NEOGENOMICS INC (NEO)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Net revenue | 181,330 | 167,824 | 164,502 | |
| Cost of revenue | 104,072 | 92,944 | 92,008 | |
| Gross profit | 77,258 | 74,880 | 72,494 | |
| Restructuring charges | - | 1,009 | 1,544 | |
| Sales and marketing | 24,075 | 20,415 | 21,677 | |
| Restructuring charges | - | - | - | |
| Research and development | 9,023 | 7,684 | 7,886 | |
| General and administrative | 71,747 | 66,969 | 63,328 | |
| Impairment charges (note 5) | 20,041 | - | - | |
| Total operating expenses | 124,886 | 96,077 | 94,435 | |
| Loss from operations | -47,628 | -21,197 | -21,941 | |
| Interest income | 2,263 | 4,673 | 4,592 | |
| Interest expense | 933 | 1,642 | 1,666 | |
| Other (income) expense, net | 482 | 317 | -2 | |
| Loss before taxes | -45,816 | -17,849 | -19,017 | |
| Income tax benefit | -724 | -150 | -375 | |
| Net loss | -45,092 | -17,699 | -18,642 | |
| Net loss | - | -17,699 | -18,642 | |
| Basic (in shares) | 127,949,000 | 126,953,000 | 126,405,000 | |
| Diluted (in shares) | 127,949,000 | 126,953,000 | 126,405,000 | |